Colorectal Cancer NGS Panel

This 43-gene panel finds actionable mutations for targeted therapy, helping patients with metastatic colorectal cancer (mCRC) to improve outcomes.


Research Use Product


Research Service

Early Detection/Screening


Therapy Selection

Therapy Monitoring

Introducing OptiSeq™ Colorectal Cancer NGS Panel

OptiSeq ™ Colorectal cancer NGS Panel determines genetic alterations in diagnosed colorectal cancer patients for actionable target therapy selections, according to the NCCN (National Comprehensive Cancer Network) guidelines.

Simple blood test: only 2 tubes of blood needed

Covers 43 genes and detects 462 genetic alterations, including single nucleotide variants (SNV), genetic rearrangement, and microsatellite instability

Analytical sensitivity: 0.25% VAF (10 ng DNA input) or 0.1% VAF (40 ng DNA input)

Clinical sensitivity and specificity: 88% and 100%, respectively

Who will benefit from OptiSeq™?

The OptiSeq™ Cancer NGS Panel covers the detection of KRAS (codons 12,13,59,61,117 and 146), NRAS (codons 12,13,59,61,117 and 146), BRAFV600E, ERBB2 amplification, and microsatellite instability covered in the NCCN (National Comprehensive Cancer Network) guideline for metastatic colorectal cancer (mCRC) targeted therapy.


CLIA labs that value and validate the panel for targeted therapy selection

Clinical Studies/Trails

Clinical studies or clinical trials that use this panel to profile CRC patients before and/or after drug testing.

Once colorectal cancer is diagnosed, using clinical NGS to identify actionable genetic alterations is critical for targeted therapy.

Although monoclonal antibodies against EGFR, such as cetuximab and panitumumab, can be used to treat patients to control colorectal cancer cell growth, patients with mutations present in other RAS/RAF genes, for instance, will not respond to the anti-EGFR therapy.

The NCCN ((National Comprehensive Cancer Network)) guidelines recommend the following tests:


All patients with mCRC should be tested for NRAS/KRAS and BRAF mutations


MSI testing is recommended for patients with mCRC


Trastuzumab and pertuzumab therapy option is added for ERBB2 amplification and wildtype RAS patients

The DiaCarta Offerings


  • OptiSeq™ Colorectal Cancer NGS Panel is a research use product.
  • Pack size is 24-reaction.
  • Catalog Number: DC-50-0005R.


OptiSeq™ Colorectal Cancer NGS Panel is available at DiaCarta as a research use service. 

Simple blood test: only 2 tubes of blood needed

Fast turnaround time: report ready in 7 business days upon sample receipt